Azuma, Junichi <br/><br/>
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.  [electronic resource] 

 -  European journal of clinical pharmacology  Jan 2012 
 - 29-37 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-1041 
<br/><br/><label>Standard No.: </label>10.1007/s00228-011-1094-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antipsychotic Agents--adverse effects<br/>Aripiprazole<br/>Biotransformation<br/>Cytochrome P-450 CYP2D6--genetics<br/>Cytochrome P-450 CYP2D6 Inhibitors<br/>Cytochrome P-450 CYP3A<br/>Cytochrome P-450 CYP3A Inhibitors<br/>Drug Interactions<br/>Enzyme Inhibitors--adverse effects<br/>Fluvoxamine--adverse effects<br/>Genetic Association Studies<br/>Half-Life<br/>Humans<br/>Japan<br/>Male<br/>Metabolic Clearance Rate--drug effects<br/>Paroxetine--adverse effects<br/>Piperazines--adverse effects<br/>Polymorphism, Genetic<br/>Quinolones--adverse effects<br/>Serotonin 5-HT2 Receptor Antagonists--adverse effects<br/>Selective Serotonin Reuptake Inhibitors--adverse effects<br/>Young Adult